have demonstrated the prognostic utility of CLR and similar CRP-based ratios in lung cancer patients receiving immunotherapy or chemotherapy, linking their elevation to an immunosuppressive state (21, 23). The gene discussed is DCLK3; the disease is lung carcinoma.